Clinical Trials Directory

Trials / Completed

CompletedNCT04121793

Objective Quality of Life Detection Validation

DiSCERN Phase I - Objective Quality of Life Detection Validation

Status
Completed
Phase
Study type
Observational
Enrollment
10 (actual)
Sponsor
Great Lakes NeuroTechnologies Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this research study is to: * Collect data to use in the development of a standardized tool for identifying patients with Parkinson's disease (PD) who would benefit from advanced therapies (AT) such as deep brain stimulation (DBS) and drug pumps. * Determine the level to which specific activities reflect with quality of life in individuals with PD. * Obtain feedback from individuals with Parkinson's disease and clinicians on the usability of the system.

Detailed description

The investigators aim to develop a standardized tool for identifying patients with Parkinson's disease (PD) who would benefit from advanced therapies (AT) and identify when AT recipients are in need of a therapy adjustment. This system will integrate ambulatory PD monitoring with context aware activity detection as the daily activities a patient performs are often the best predictors of quality of life (QoL). In this study the Kinesia 360 system will collect motion data to measure tremor, bradykinesia (slow movement), and dyskinesia (involuntary movements) from individuals with PD to track their symptoms throughout the day. A smartphone will collect information on subject location and activity using the GPS, accelerometers, and microphone within the phone to find correlations between activity and patient wellness. This data will be used to improve detection over time and predict whether patients are candidates for advanced therapies.

Conditions

Interventions

TypeNameDescription
DEVICEKinesia 360 and Smartphone sensorsData will be recorded from the Kinesia 360 system and smartphone sensors using the AWARE Framework.

Timeline

Start date
2019-09-20
Primary completion
2020-06-30
Completion
2020-06-30
First posted
2019-10-10
Last updated
2020-08-12

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04121793. Inclusion in this directory is not an endorsement.